Back to top
more

Entera Bio (ENTX)

(Delayed Data from NSDQ)

$1.82 USD

1.82
114,465

+0.02 (1.11%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $1.85 +0.03 (1.65%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 8.33% and 8.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for August 19th

by Zacks Equity Research

ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.

Zacks Equity Research

Entera (ENTX) Up on Positive Results From Osteoporosis Drug

by Zacks Equity Research

Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.

Zacks Equity Research

Entera Bio (ENTX) is Overbought: Is A Drop Coming?

by Zacks Equity Research

Entera Bio (ENTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Zacks Equity Research

Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year

by Zacks Equity Research

Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis

Zacks Equity Research

The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio

Kinjel Shah headshot

4 Biotech Stocks That Have Already Doubled This Year So Far

by Kinjel Shah

Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.